Opportunity Information: Apply for RFA HG 13 007
Apply for RFA HG 13 007
- The National Institutes of Health in the health sector is offering a public funding opportunity titled "Revolutionary Genome Sequencing Technologies The 1000 Genome (SBIR R43/R44)" and is now available to receive applicants.
- Interested and eligible applicants and submit their applications by referencing the CFDA number(s): 93.172 Human Genome Research.
- This funding opportunity was created on Oct 21, 2013 and posted on Jun 26, 2013.
- Applicants must submit their applications by Nov 1, 2013. (Agency may still review applications by suitable applicants for the remaining/unused allocated funding in 2026.)
- The funding agency has allocated a total of $2,000,000.00 to eligible and selected applicants.
- Eligible applicants include: Small businesses.
- Other Eligible Applicants include the following Non domestic (non U.S.) Entities (Foreign Institutions) are not eligible to apply. Non domestic (non U.S.) components of U.S. Organizations are not eligible to apply. Foreign components, as defined in the NIH Grants Policy Statement, may be allowed.
[Watch] Creating a grant proposal using the step-by-step wizard inside the applicant portal:
Opportunity Summary:
The funding opportunity titled "Revolutionary Genome Sequencing Technologies: The $1000 Genome (SBIR R43/R44)" is a National Human Genome Research Institute (NHGRI) solicitation under the National Institutes of Health (NIH) aimed at pushing DNA sequencing technology to a major cost and performance milestone. The core purpose is to support small businesses developing genuinely new approaches that can make high-quality sequencing of a mammalian-sized genome possible for roughly $1,000. In practical terms, NHGRI is looking for breakthroughs that dramatically reduce sequencing cost while maintaining (or improving) data quality, accuracy, and overall utility for research and eventual clinical or population-scale use.
This solicitation is structured as an SBIR opportunity using the R43 and R44 mechanisms, meaning it is specifically designed for small business applicants to move innovations from early feasibility work into more advanced development. Applicants can propose complete, end-to-end sequencing platforms, but the announcement also explicitly welcomes projects focused on critical underlying components that could unlock a $1,000-genome system. That can include things like novel chemistry, sample preparation, single-molecule approaches, improved base-calling and error-correction strategies, alternative detection modalities, new nanopore or non-optical sensing concepts, radically different library construction workflows, new approaches to amplification (or eliminating amplification), or improved throughput and automation that reduce per-genome labor and consumables. The emphasis is on enabling technology rather than incremental tuning of existing systems, with the expectation that meaningful cost reduction and performance gains will require creative technical leaps.
A notable feature of this FOA is its explicit encouragement of methods outside the mainstream approaches being pursued at the time. NHGRI signals that it is interested in unconventional ideas that could plausibly surpass current trajectories, even if those ideas carry significant technical risk. The announcement also highlights that high-risk/high-payoff applications are appropriate, which is an important cue about review expectations: proposals do not need to be fully proven at the outset, but they do need a credible scientific rationale, a clear development plan, and well-defined milestones showing how the team will test feasibility and reduce the key uncertainties. In other words, the program is trying to create room for big bets, provided the engineering and experimental plan is disciplined and testable.
From an administrative standpoint, this is a discretionary grant opportunity with a health-related R&D focus under CFDA 93.172 (Human Genome Research). The estimated total funding listed for the opportunity is $2,000,000, and there is no cost sharing or matching requirement. Eligibility is limited to small businesses, consistent with SBIR rules. Foreign (non-U.S.) entities are not eligible to apply, and non-U.S. components of U.S. organizations are also not eligible; however, foreign components may be permitted in certain cases as defined by the NIH Grants Policy Statement, which typically means they must be strongly justified and provide a unique capability not readily available domestically.
Key dates included in the record show the opportunity was posted on June 26, 2013, with an original closing date of October 17, 2013, and a current closing date listed as November 1, 2013. The archive date is December 1, 2013, indicating the solicitation is no longer active, but the summary remains useful as a reference point for the type of innovations NHGRI has historically sought under the "$1,000 genome" banner. The funding opportunity number is RFA-HG-13-007, and the full announcement was made available through the NIH grants guide at http://grants.nih.gov/grants/guide/rfa-files/RFA-HG-13-007.html. For access or technical issues with the electronic announcement, NIH provided contact through the NIH Office of Extramural Research (OER) webmaster (FBOWebmaster@OD.NIH.GOV).
Overall, the opportunity is best understood as NHGRI using the SBIR pipeline to accelerate disruptive sequencing technology development, whether through whole-system prototypes or enabling subsystems, with the explicit benchmark of making a mammalian genome sequence achievable at around $1,000 without compromising quality. The solicitation’s language and structure make it clear that NHGRI was aiming to catalyze transformative, non-incremental advances that could change the economics and scalability of genomics.
FAQs: Revolutionary Genome Sequencing Technologies: The $1000 Genome (SBIR R43/R44)
What is the title of this funding opportunity?
The funding opportunity is titled "Revolutionary Genome Sequencing Technologies: The $1000 Genome (SBIR R43/R44)."
Which agency and institute offered this opportunity?
This solicitation was offered by the National Human Genome Research Institute (NHGRI) under the National Institutes of Health (NIH).
What is the main purpose of the program?
The purpose is to support small businesses developing genuinely new DNA sequencing approaches that can enable high-quality sequencing of a mammalian-sized genome for roughly $1,000, while maintaining or improving data quality, accuracy, and overall utility for research and eventual clinical or population-scale use.
What does the "$1,000 genome" benchmark mean in practical terms?
It refers to achieving sequencing of a mammalian-sized genome at an approximate cost of $1,000, with an emphasis on keeping quality and accuracy high enough to remain useful for research and to support eventual clinical and large-scale population applications.
What funding mechanisms are used (R43/R44), and what do they imply?
This is an SBIR opportunity using the R43 and R44 mechanisms. It is designed for small businesses to move innovations from early feasibility work (R43) into more advanced development (R44) as part of an SBIR pipeline.
Who is eligible to apply?
Eligibility is limited to small businesses, consistent with SBIR rules.
Are foreign (non-U.S.) entities eligible to apply?
No. Foreign (non-U.S.) entities are not eligible to apply.
Are non-U.S. components of U.S. organizations eligible?
No. Non-U.S. components of U.S. organizations are also not eligible.
Are foreign components allowed in any circumstances?
Foreign components may be permitted in certain cases as defined by the NIH Grants Policy Statement, typically requiring strong justification and a unique capability not readily available domestically.
Is cost sharing or matching required?
No. The opportunity states there is no cost sharing or matching requirement.
How much total funding was estimated for this opportunity?
The estimated total funding listed for the opportunity is $2,000,000.
What is the program focus area or CFDA listing?
It is a discretionary grant opportunity with a health-related R&D focus under CFDA 93.172 (Human Genome Research).
What kinds of projects were encouraged?
The solicitation supported breakthroughs that dramatically reduce sequencing costs while maintaining or improving sequencing quality and performance. It encouraged genuinely new approaches rather than incremental tuning of existing systems.
Could applicants propose an end-to-end sequencing platform?
Yes. Applicants could propose complete, end-to-end sequencing platforms.
Could applicants propose only a component or subsystem rather than a full platform?
Yes. The announcement explicitly welcomed projects focused on critical underlying components that could unlock a $1,000-genome system.
What are examples of enabling components or approaches mentioned in the opportunity summary?
Examples include novel chemistry, sample preparation innovations, single-molecule approaches, improved base-calling and error-correction strategies, alternative detection modalities, new nanopore or non-optical sensing concepts, radically different library construction workflows, new approaches to amplification (or eliminating amplification), and improved throughput and automation to reduce per-genome labor and consumables.
What level of innovation was NHGRI looking for?
The emphasis was on enabling technology and creative technical leaps, rather than incremental improvements to existing systems, reflecting the view that meaningful cost reduction and performance gains would require transformative advances.
Did the program encourage unconventional or high-risk ideas?
Yes. A notable feature was explicit encouragement of methods outside mainstream approaches, and it stated that high-risk/high-payoff applications were appropriate.
How were applicants expected to handle technical risk in their proposals?
While proposals did not need to be fully proven at the outset, they were expected to include a credible scientific rationale, a clear development plan, and well-defined milestones showing how feasibility would be tested and key uncertainties reduced.
What is the funding opportunity number?
The funding opportunity number is RFA-HG-13-007.
When was the opportunity posted?
The opportunity was posted on June 26, 2013.
What were the closing dates listed for this opportunity?
The record lists an original closing date of October 17, 2013, and a current closing date of November 1, 2013.
Is this opportunity still active?
No. The archive date is December 1, 2013, indicating the solicitation is no longer active.
Where could applicants find the full announcement?
The full announcement was made available through the NIH grants guide at http://grants.nih.gov/grants/guide/rfa-files/RFA-HG-13-007.html.
Who was listed as a contact for access or technical issues with the electronic announcement?
For access or technical issues, NIH provided contact through the NIH Office of Extramural Research (OER) webmaster at FBOWebmaster@OD.NIH.GOV.
What is the overall intent of the solicitation in plain terms?
It aimed to use the SBIR pipeline to accelerate disruptive sequencing technology development, whether through whole-system prototypes or enabling subsystems, with the explicit goal of making a mammalian genome sequence achievable at around $1,000 without compromising quality.
Browse more opportunities from the same category: Health
Next opportunity: Revolutionary Genome Sequencing Technologies The 1000 Genome (R21)
Previous opportunity: Revolutionary Genome Sequencing Technologies The 1000 Genome (R01)
USGrants.org Applicant Portal:
Are you interested in learning about about how to apply for this government funding opportunity? You can create a free applicant account and receive instant access to our applicant portal that many business owners like you have benefited from.
Apply for RFA HG 13 007
[Watch] how do funding administrators access proposals?
Applicants also applied for:
Applicants who have applied for this opportunity (RFA HG 13 007) also looked into and applied for these:
| Funding Opportunity |
|---|
| Revolutionary Genome Sequencing Technologies The 1000 Genome (R21) Apply for RFA HG 13 006 Funding Number: RFA HG 13 006 Agency: National Institutes of Health Category: Health Funding Amount: $200,000 |
| Mentored Clinical Scientist Research Career Development Award in Tobacco Control Regulatory Research (K08) Apply for RFA OD 13 013 Funding Number: RFA OD 13 013 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Mentored Research Scientist Career Development Award in Tobacco Control Regulatory Research (K01) Apply for RFA OD 13 014 Funding Number: RFA OD 13 014 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Transition Career Development Award in Tobacco Control Regulatory Research (K22) Apply for RFA OD 13 015 Funding Number: RFA OD 13 015 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Pathway to Independence Award in Tobacco Control Regulatory Research (K99/R00) Apply for RFA OD 13 016 Funding Number: RFA OD 13 016 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Resource Related Research Projects for Development of Animal Models and Related Materials (R24) Apply for PAR 13 253 Funding Number: PAR 13 253 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Sexually Transmitted Infections Cooperative Research Centers (STI CRC) (U19) Apply for RFA AI 13 043 Funding Number: RFA AI 13 043 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Supporting the Continuum of Care Building Ryan White Program Grantee Capacity to Enroll Eligible Clients in Affordable Care Act Health Coverage Programs Apply for HRSA 13 281 Funding Number: HRSA 13 281 Agency: Health Resources and Services Administration Category: Health Funding Amount: Case Dependent |
| Support for Demonstration Ombudsman Programs Serving Beneficiaries of Financial Alignment Models for Medicare Medicaid Enrollees Apply for CMS 1J1 13 001 Funding Number: CMS 1J1 13 001 Agency: Centers for Medicare Medicaid Services Category: Health Funding Amount: $125,000 |
| NIAID Investigator Initiated Program Project Applications (P01) Apply for PAR 13 254 Funding Number: PAR 13 254 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Innovative Assays to Quantify the Latent HIV Reservoir (R21) Apply for RFA AI 13 038 Funding Number: RFA AI 13 038 Agency: National Institutes of Health Category: Health Funding Amount: $200,000 |
| Aging Studies in the Pulmonary System (R01) Apply for PA 13 255 Funding Number: PA 13 255 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Healthy Markets Activity Apply for USAID VIETNAM SOL 486 13 000022 Funding Number: USAID VIETNAM SOL 486 13 000022 Agency: Thailand USAID Bangkok Category: Health Funding Amount: $15,000,000 |
| NINDS Neuroscience Development for Advancing the Careers of a Diverse Research Workforce (R25) Apply for PAR 13 256 Funding Number: PAR 13 256 Agency: National Institutes of Health Category: Health Funding Amount: $250,000 |
| NIA Program Project Applications (P01) Apply for PAR 13 258 Funding Number: PAR 13 258 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Limited Competition Extramural Research Facilities Restoration Program Hurricane Sandy Disaster Relief (C06) Apply for RFA OD 13 007 Funding Number: RFA OD 13 007 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Improvement of Animal Models for Stem Cell Based Regenerative Medicine (R24) Apply for PAR 13 252 Funding Number: PAR 13 252 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Providing Support for the Collaborative Improvement and Innovation Network (CoIIN) to Reduce Infant M Apply for HRSA 13 282 Funding Number: HRSA 13 282 Agency: Health Resources and Services Administration Category: Health Funding Amount: $3,000,000 |
| Morbidity Management and Disability Prevention for Blinding Trachoma and Lymphatic Filariasis Apply for SOL OAA 13 000107 Funding Number: SOL OAA 13 000107 Agency: Agency for International Development Category: Health Funding Amount: $35,000,000 |
| Secondary Analyses of Alcohol and Chronic Disease (R21) Apply for PA 13 251 Funding Number: PA 13 251 Agency: National Institutes of Health Category: Health Funding Amount: $200,000 |
Grant application guides and resources
It is always free to apply for government grants. However the process may be very complex depending on the funding opportunity you are applying for. Let us help you!
Apply for Grants
Premium leads for funding administrators, grant writers, and loan issuers
Thousands of people visit our website for their funding needs every day. When a user creates a grant proposal and files for submission, we pass the information on to funding administrators, grant writers, and government loan issuers.
If you manage government grant programs, provide grant writing services, or issue personal or government loans, we can help you reach your audience.
Subscribe to Leads
Request more information:
Would you like to learn more about this funding opportunity, similar opportunities to "RFA HG 13 007", eligibility, application service, and/or application tips? Submit an inquiry below:
Don't forget to subscribe to our grant alerts mailing list to receive weekly alerts on new and updated grant funding opportunities like this one in your email.